Clinical trials: Anticoagulant Drugs
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Thrombus of Left Ventricle
Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
The investigators' primary objective is to assess whether a difference in the occurrence of bleeding events exist between patients with LVT treated with DOACs as compared to those treated with VKAs.
- Trial name
- LV-Thrombus (NCT05028777)
- Where
- Switzerland
- Volunteers
- 98 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anticoagulant
Determinants of Oral Anticoagulants' Activity
The primary objective of the present study is to determine the clinical, biological and genetic determinants of the anticoagulant activity in patients treated with either anti-IIa or anti Xa oral anticoagulants.
- Trial name
- ANTIGOAG (NCT03172546)
- Testing
- PK-PD genetic polymorphisms
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Lille
Atrial Fibrillation
Validation of Predictors of OAC Initiation Using EMR Data
The objectives of this study are, first, to identify select clinical covariates from electronic medical records (EMR) that might be associated with initiation of oral anticoagulant medications (dabigatran or warfarin) in patients…
- Trial name
- NCT03006341
- Testing
- Dabigatran etexilate, Warfarin
- Where
- United States
- Volunteers
- 140,187 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Chronic Subdural Hematoma, Anticoagulant-induced Bleeding
Management of Anticoagulants and Antithrombotics in Patients With CSDH
Primary objective of the study will be to compare, up to 6 months after surgery, number of relapses (post operative re-bleeding) or intracerebral hemorrhage (others than subdural hematomas) and thromboembolic or cardiovascular…
- Conditions
- Chronic Subdural Hematoma, Anticoagulant-induced Bleeding, Thromboembolic Stroke, Cardiovascular Stroke
- Trial name
- THERCA (NCT05079295)
- Testing
- CSDH evacuation
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Hospital of Ferrara
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE), Prevention
- Trial name
- NCT07124819
- Testing
- Sodium enoxaparin, Dimolegin
- Where
- 8 sites in Russia
- Volunteers
- 215 people
- Sponsor
- Avexima Diol LLC
Atrial Fibrillation
Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients
Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely…
- Trial name
- NCT04062071
- Testing
- no intervention
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Atrial Fibrillation (AF), VTE
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure…
- Trial name
- PAUSE 2 RCT (NCT06957366)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 920 people
- Sponsor
- McMaster University
Myeloma, Venous Thromboembolism
Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
To evaluate: the incidence of venous thromboembolic event (VTE) the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an…
- Trial name
- MYELAXAT (NCT02066454)
- Testing
- Apixaban
- Where
- 19 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Grenoble
Thromboembolic Disease
Safety of Direct Oral Anticoagulant During Pregnancy
Pregnancy is a major risk factor of thromboembolic disease (2 to 10 increased risk of thromboembolic event for pregnant women). This risk is related to the physiological changes inducing venous stasis and hypercoagulability.
- Trial name
- SACOD (NCT06179823)
- Where
- France
- Volunteers
- 1,755,558 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Atrial Fibrillation (AF)
AF-CARD Registry (Real-World Clinical Practice Registry of Patients With Atrial Fibrillation)
Multicenter Non-Interventional Real-World Clinical Practice Registry of Patients with Atrial Fibrillation. The primary objective of the registry is an epidemiological assessment of the characteristics, clinical outcomes, and…
- Trial name
- AF-CARD (NCT07437456)
- Where
- Russia
- Volunteers
- 3,500 people
- Sponsor
- Eurasian Association of Therapists
Mitral Stenosis, Rheumatic Heart Disease
RIvoraxaban in Mitral Stenosis
In this randomized controlled clinical trial, patients with moderate to severe mitral valve stenosis (MS) and atrial fibrillation (AF) will be enrolled into the study.Participants will be divided into two groups based on the…
- Conditions
- Mitral Stenosis, Rheumatic Heart Disease, Atrial Fibrillation, Anticoagulant Adverse Reaction
- Trial name
- RISE MS (NCT03926156)
- Testing
- Rivaroxaban, Warfarin
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Acute Chest Syndrome, Sickle Cell Disease
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
The purpose of this study is to determine the feasibility of performing a larger multicenter phase III trial to assess the effects of unfractionated heparin (UFH) in acute chest syndrome (ACS).
- Trial name
- NCT02098993
- Testing
- Unfractionated heparin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Craig Seaman
Percutaneous Coronary Intervention, High Bleeding Risk
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking. Methods.
- Conditions
- Percutaneous Coronary Intervention, High Bleeding Risk, Acute Coronary Syndromes, Anticoagulant Therapy
- Trial name
- BRIGHT-HBR (NCT07383155)
- Testing
- Anticoagulant Therapy
- Volunteers
- 5,270 people
- Sponsor
- Shenyang Northern Hospital
Recurrent Pregnancy Loss, Antiphospholipid Antibody Syndrome
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.
- Trial name
- HepASA (NCT00564174)
- Testing
- Low molecular weight heparin and low dose aspirin, Low dose aspirin
- Where
- 2 sites in Canada
- Volunteers
- 88 people
- Sponsor
- Mount Sinai Hospital, Canada
Healthcare Quality Indicators, Inappropriate Prescribing
Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions
This research focuses on the development and validation of indicators on the appropriateness of oral anticoagulant prescriptions.
- Conditions
- Healthcare Quality Indicators, Inappropriate Prescribing, Anticoagulant Drugs, Atrial Fibrillation
- Trial name
- PACHA (NCT02898090)
- Where
- 4 sites in France
- Volunteers
- 1,213 people
- Sponsor
- University Hospital, Bordeaux
Venous Thromboembolism, Deep Vein Thrombosis
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
The protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- GARFIELD-VTE (NCT02155491)
- Where
- United States
- Volunteers
- 10,679 people
- Sponsor
- Thrombosis Research Institute